← Back to Search

Monoclonal Antibodies

New Imaging Technique for Kidney Cancer

Phase 2
Recruiting
Led By Brian Shuch
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Subjects must have undergone definitive treatment of their primary tumor (partial/radical nephrectomy) +/- resection of metastatic disease to no evidence of disease (NED) with a prior nephrectomy < 2 years)
Histologically confirmed clear cell renal cell carcinoma (RCC) (ccRCC) (based on partial/radical nephrectomy/metastasectomy)
Must not have
Known inability to remain still and lie flat during imaging procedure
Any evidence of residual disease or known metastasis at the time of planned 89Zr-DFO-GmAb administration
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Summary

This trial is testing a new imaging technique called 89Zr-DFO-GmAb positron emission tomography (PET)/computed tomography (CT) to see if it is better than the

Who is the study for?
This trial is for individuals who have undergone surgery for clear cell renal cell cancer and are being monitored for possible recurrence of the disease. It's not specified who can't join, but typically, participants need to meet certain health standards.
What is being tested?
The study is testing a new scan called 89Zr-DFO-GmAb PET/CT against the standard contrast-enhanced CT to see if it's better at finding recurrent kidney cancer after surgery. The investigational scan uses a radioactive tracer that targets tumor cells.
What are the potential side effects?
Potential side effects may include reactions to the tracer or contrast agent used in scans, such as allergic reactions or discomfort at injection site. Radiation exposure from PET/CT is also a consideration.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I had surgery to remove my kidney cancer and any spread, with no signs of cancer now, all within the last 2 years.
Select...
My kidney cancer was confirmed by surgery.
Select...
I can stay still and lie flat for up to an hour.
Select...
I am 18 years old or older.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I cannot stay still or lie flat during scans.
Select...
I have signs of cancer remaining or spreading at the time of my planned treatment.
Select...
I cannot have CT scans with iodine-based contrast due to health reasons.
Select...
I am not pregnant or breastfeeding.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Lesion detection rate
Secondary study objectives
Change in management and perceived clinical utility of the unblinded read/report of positron emission tomography/ computed tomography (PET/CT)
Incidence of adverse events (AEs)
Positive predictive value (PPV)
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Diagnostic (89Zr-DFO-GmAb PET/CT)Experimental Treatment7 Interventions
Patients receive 89Zr-DFO-GmAb IV over 3 minutes on day 0 then undergo whole body PET/CT and SOC diagnostic contrast-enhanced CT scan on day 7. Patients also blood sample collection on study. In addition, patients may undergo bone scan and CT or MRI of the brain on study as clinically indicated.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Biospecimen Collection
2004
Completed Phase 3
~2020
Bone Scan
2015
Completed Phase 2
~50
Positron Emission Tomography
2011
Completed Phase 2
~2200
Magnetic Resonance Imaging
2017
Completed Phase 3
~1160
Computed Tomography
2017
Completed Phase 2
~2740

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor
369 Previous Clinical Trials
29,338 Total Patients Enrolled
Telix Pharmaceuticals (Innovations) Pty LimitedIndustry Sponsor
18 Previous Clinical Trials
1,306 Total Patients Enrolled
Brian ShuchPrincipal InvestigatorUCLA / Jonsson Comprehensive Cancer Center
2 Previous Clinical Trials
100 Total Patients Enrolled
~61 spots leftby Dec 2029
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top